Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Narrowing the Gap for Hematopoietic Stem Cell Transplantation in the East-Mediterranean/African Region: Comparison With Global Hsct Indications and Trends Publisher Pubmed



Baldomero H1 ; Aljurf M2 ; Zaidi SZA3 ; Hashmi SK2 ; Ghavamzadeh A4 ; Elhaddad A5 ; Hamladji RM6 ; Ahmed P7 ; Torjemane L8 ; Abboud M9 ; Tbakhi A10 ; Khabori MA11 ; El Quessar A12 ; Bazuaye N13 Show All Authors
Authors
  1. Baldomero H1
  2. Aljurf M2
  3. Zaidi SZA3
  4. Hashmi SK2
  5. Ghavamzadeh A4
  6. Elhaddad A5
  7. Hamladji RM6
  8. Ahmed P7
  9. Torjemane L8
  10. Abboud M9
  11. Tbakhi A10
  12. Khabori MA11
  13. El Quessar A12
  14. Bazuaye N13
  15. Bekadja MA14
  16. Adil S15
  17. Fahmy O16
  18. Ramzi M17
  19. Ibrahim A18
  20. Alseraihy A2
  21. Ben Abdejalil N8
  22. Sarhan M10
  23. Huneini MA11
  24. Mahmal L19
  25. Elsolh H2
  26. Hussain F2
  27. Nassar A5
  28. Alhashmi H20
  29. Hamidieh AA4
  30. Pasquini M21
  31. Kodera Y22
  32. Kroger N23
  33. Mohty M24
  34. Jaimovich G25
  35. Rolon JM26
  36. Paulson K27
  37. Greinix H28
  38. Weisdorf D29
  39. Horowitz M20
  40. Nunez J30
  41. Gratwohl A1
  42. Passweg J1
  43. Koh M31
  44. Szer J32
  45. Niederwieser D33
  46. Novitzky N34

Source: Bone Marrow Transplantation Published:2019


Abstract

Hematopoietic Stem Cell Transplantation (HSCT) activity was evaluated in the African (AFR)/EMRO region and compared to the global activity for the years 2006–2013. Data were obtained from 1570 teams in the 6 WHO continental regions. Of these, 29 (1.85%) of all teams were active in 12 of the 68 AFR/EMRO countries. They reported 2.331 (3.3%) of the worldwide 71.036 HSCT, and a transplant rate of 32.8 (TR; HSCT/10 million inhabitants; worldwide 128.5). This reflects still the lowest regional TR despite an increase of 90% since 2006. HSCT activity in AFR/EMRO countries was characterized by a higher use of allogeneic compared to autologous HSCT, an almost exclusive use of family donors, including haploidentical family donors. These findings contrast with the prevalence of autologous over allogeneic HSCT, and a higher frequency of unrelated HSCT in other parts of the world. Of note, the increase by 200% in HSCT for hemoglobinopathies from 2006 to 2013 (72 per year) in the AFR/EMRO region. This reflects the specific role of HSCT for these disease categories with high prevalence and incidence in the AFR/EMRO region. This report provides information for the competent authorities to foster adequate infrastructure. It urges transplant organization to optimize their cooperation. © 2018, Macmillan Publishers Limited, part of Springer Nature.
Other Related Docs
12. Hsct at a Glance, Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation (2024)
16. Abo Incompatibility and Hematopoietic Stem Cell Transplantation Outcomes, International Journal of Hematology-Oncology and Stem Cell Research (2017)